Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation (Q38615230)

4 September 2017

Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation (English)

1 reference

4 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Anthony Rodgers

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Anthony Rodgers

series ordinal

2

1 reference

4 September 2017

1 December 2015

1 reference

Current cardiology reports

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497041%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11886-015-0673-x

5 June 2020

exact match

0 references

cites work

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Two decades of progress in preventing vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Balancing the dilution and oddity effects: decisions depend on body size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Randomized Polypill crossover trial in people aged 50 and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0673-X

WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE)

21 January 2018

1 reference

12 December 2020

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.

1 reference

12 December 2020

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk

1 reference

12 December 2020

Gaps in cardiovascular disease risk management in Australian general practice

1 reference

12 December 2020

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study.

1 reference

12 December 2020

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.

1 reference

12 December 2020

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care

1 reference

12 December 2020